Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sex-related difference analyses of efficacy and safety in clinical trials of direct-acting antivirals to treat chronic HCV genotype 1 and 3 infections.

Journal of viral hepatitis - 1 Feb 2024

Zhou Shuang, Qi Karen, Bersoff-Matcha Susan J, Mishra Poonam, Struble Kimberly

Abstract excerpt

This study aims to identify clinically meaningful sex differences in efficacy and selected safety adverse events for the treatment of chronic hepatitis C virus infection (HCV) or HIV/HCV co-infection in those receiving combination direct-acting antiviral (DAA) regimens. Our assessment was based on adult trial participants treated at the approved DAA dosage and treatment duration from 40 phase 3 clinical trials...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Sex Characteristics

Share to Sustained Virologic Response

Source

Identifiers

PMID: 38111976
DOI: 10.1111/jvh.13901

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sex-related difference analyses of efficacy and safety in clinical trials of direct-acting antivirals to treat chronic HCV genotype 1 and 3 infections.PMID 38111976Read ↗

Direct-acting antivirals in women of reproductive age infected with hepatitis C virus.Semantic proximity Read ↗

Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.Semantic proximity Read ↗

Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.Semantic proximity Read ↗

Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.Semantic proximity Read ↗

Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.Semantic proximity Read ↗

Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis.Semantic proximity Read ↗

Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population.Semantic proximity Read ↗

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.Semantic proximity Read ↗

Gender influence on treatment of chronic hepatitis C genotype 1.Semantic proximity Read ↗

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.Semantic proximity Read ↗

Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus.Semantic proximity Read ↗

Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.